Related Experiment Video

Updated: Jun 13, 2025

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.0K

Therapeutics involved in managing initial and recurrent Clostridium difficile infection: An updated literature review

Vignesh K Nagesh1, Hadrian Hoang-Vu Tran2, Daniel Elias2

  • 1Department of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, United States. vgneshkrishnan@gmail.com.

World Journal of Gastrointestinal Pharmacology and Therapeutics
|September 16, 2024
PubMed

Insights

Clostridium difficile infection (CDI) is rising due to antibiotic use altering the gut microbiome. New treatments are being explored to combat increasing drug resistance and recurrent infections in high-risk patients.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Gastroenterology

Background:

  • Clostridium difficile infection (CDI) incidence is increasing, linked to antibiotic use and gut microbiome disruption.
  • Recurrent CDI and antibiotic resistance are significant challenges, particularly in elderly, critical care, and immunocompromised populations.
  • CDI can lead to severe complications like septic shock and fulminant colitis.

Purpose of the Study:

  • To review current treatment modalities for CDI.
  • To explore emerging treatments and preventative strategies for CDI.
  • To discuss the challenges associated with CDI treatment and resistance.

Main Methods:

  • Literature review of current and emerging CDI treatments.
  • Analysis of factors contributing to CDI recurrence and drug resistance.
  • Examination of novel therapeutic approaches and preventative measures.

Main Results:

  • Limited antibiotic options and increasing drug resistance complicate CDI management.
  • Newer treatments like bezlotoxumab and fecal microbiota transplant show promise.
  • Asymptomatic carriers and resistance pose a threat to healthcare systems.

Conclusions:

  • Effective management of CDI requires addressing antibiotic resistance and recurrence.
  • Novel therapies and preventative strategies are crucial for combating CDI.
  • Continued research is needed to overcome challenges in CDI treatment and prevention.
Keywords:
AntibioticsBezlotoxumabClostridium difficileFecal microbiota transplantFidaxomicinPreventionVancomycin

More Related Videos

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

38.7K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.1K

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
118
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
111